cerca CERCA
Mercoledì 12 Maggio 2021
Aggiornato: 14:34
Temi caldi

agreement

Kazia Licenses Global Rights to EVT801, a Novel, First-in-Class, Clinic-Ready, VEGFR3 Inhibitor, from Evotec SE

SYDNEY, April 19, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has entered into a worldwide exclusive licensing agreement and a master services agreement with Evotec SE (FRA: EVT), a leading European drug discovery and development company, for EVT801, a small-molecule, first-in-class oncology drug candidate. Kazia expects to launch a phase I clinical trial of EVT801 in CY2021.

alternate text

Eni, Bridgestone EMIA ink synthetic rubber deal

Italian major Eni's subsidiary Versalis has signed an accord with Bridgestone EMIA to jointly develop a joint agreement for the research, production and supply of synthetic rubber with advanced properties, Eni said in a statement.

International Consortium Led by Authentix, Inc. Finalizes License Agreement to Implement Major Track and Trace System in Pakistan

ADDISON, Texas and GAUTENG, South Africa and ISLAMABAD, Pakistan, March 10, 2021 /PRNewswire/ -- The Consortium of Authentix, Inc., MITAS Corporation and AJCL Private Limited is pleased to announce it has finalized a license agreement with Federal Board of Revenue of Pakistan to implement a track and trace system for tobacco, cement, sugar and fertilizer. The license agreement covers an initial five (5) year term as well as a three (3) year extension option.

ICHOM and LOGEX sign agreement to accelerate the implementation of value-based healthcare worldwide

LONDON, March 3, 2021 /PRNewswire/ -- The International Consortium for Health Outcomes Measurement (ICHOM) signs a multi-year agreement with Dutch health analytics company LOGEX to launch the ICHOM Global Benchmarking Platform. The collaboration will provide the healthcare community the first ever platform to benchmark patient outcomes internationally, enabling faster learning and improvements of healthcare across the globe.

Population Council and Duchesnay Announce New International License Agreement for ANNOVERA®

NEW YORK and BLAINVILLE, QC, Nov. 30, 2020 /PRNewswire/ -- Today the Population Council and Duchesnay announce an exclusive license agreement to make ANNOVERA® (segesterone acetate and ethinyl estradiol vaginal system), the first and only contraceptive fully under a woman's control to protect against unintended pregnancy for up to a year, available in Canada, Europe, Latin America, Asia and other territories. This agreement is another step toward bringing contraceptive choice, convenience and con...

L'Oréal signs license agreement with Dutch biotech Micreos, world leader in targeted bacterial biotechnology

CLICHY, France and THE HAGUE, Netherlands, Oct. 29, 2020 /PRNewswire/ -- L'Oréal and Micreos announced today the signature of a license agreement to join their expertise in biotechnology and the skin microbiome, the community of bacteria and microorganisms that live on the skin. Under the terms of the agreement, Micreos will give L'Oréal access to its endolysin, a type of active protein in the cosmetic field. With this technology, it is possible for the first time to target only unwanted bacteria...

BioInvent Completes First Licensing Agreement in Greater China, Advised by MSQ Ventures

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- M.S.Q. Ventures ("MSQ") announced today that its client, BioInvent International, AB ("BioInvent"), has successfully entered into a licensing agreement with CASI Pharmaceuticals, Inc. ("CASI") for the development and commercialization of BI-1206 in the Greater China region. BI-1206 is BioInvent's proprietary clinical stage anti-FcγRllB antibody developed to treat a variety of cancers including Non-Hodgkin's lymphoma and advanced solid tumors.

alternate text

Italy hails landmark peace deal in Sudan

Italy has welcomed the peace accord inked in the South Sudan's capital Juba at the weekend between Sudan's transitional government and rebel groups aimed at ending decades of war in which hundreds of thousands died.

Hovione Announces Partnership to Support Manufacturing of Antiviral Veklury® for COVID-19

LISBON, Portugal, Sept. 23, 2020 /PRNewswire/ -- Hovione today announced the signing of a partnership agreement with Ligand to significantly ramp up the production output of Captisol®. Captisol®, a Ligand product, is a chemically modified cyclodextrin proven to improve the solubility and stability of drugs. It is used in the formulation of Gilead's COVID-19 treatment Veklury® (remdesivir). Hovione is the sole producer of this key enabling excipient.

PHC Holdings Corporation and Ascensia Diabetes Care Announce Financing Agreement and Exclusive Global Commercial Agreement With Senseonics

TOKYO and BASEL, Switzerland, Aug. 10, 2020 /PRNewswire/ -- PHC Holdings Corporation and Ascensia Diabetes Care, a PHC Group company, today announced a strategic partnership with Senseonics Holdings, Inc., a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes. The partnership comprises a global commercialization and distribution agreement and a concurrent financing agreement.

Stevanato Group Signs an Agreement With the Coalition for Epidemic Preparedness Innovations (CEPI) to Provide Pharma Glass Vials for 2 Billion Doses of COVID-19 Vaccines Under Development

PIOMBINO DESE, Italy, June 25, 2020 /PRNewswire/ -- Italy-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, and CEPI (the Coalition for Epidemic Preparedness Innovations) - the global partnership at the forefront of funding and coordinating the development of COVID-19 vaccine candidates - signed an agreement for the supply of 100 million Type 1 Borosilicate glass vials to hold up to 2 billion doses of a vaccine against t...

ora in
Prima pagina
articoli
in Evidenza